락토바실러스 람노서스(Lactobacillus rhamnosus)의 아토피 예방 효과
최근 나온 논문 검색중에 찾은 흥미로운 기사입니다. 일단 한번 읽어보시죠.
February 10, 2012 — Infants exposed to Lactobacillus rhamnosus through diet supplements from 35 weeks' gestation through 2 years of age had a significantly lower risk for eczema and rhinoconjunctivitis. The protective effect lasted until the children were at least 4 years of age, according to a study published online February 6 in Clinical and Experimental Allergy.
락토바실러스 람노서스(Lactobacillus rhamnosus)를 임신 35주부터 2세까지 복용하면 아토피를 줄이고 알레르기 비결막염을 현저히 줄일 수 있다는 연구 결과이다. 이 효과는 적어도 4세정도까지 지속될 수 있다고 한다.
The researchers, led by Kristin Wickens, PhD, from the Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, New Zealand, and colleagues, followed 425 infants for 4 years after daily supplementation with L rhamnosus (HN001; 6 × 109 colony-forming units [cfu]/day), Bifidobacterium animalis subsp lactis (HN019; 9 × 109 cfu/day), or placebo. Mothers received supplements from 35 weeks' gestation until their child's birth, continuing to 6 months
after birth if they were breast-feeding, and all infants received supplements from birth until age 2 years.
뉴질랜드의 Kristin Wickens 박사는 임신 35주부터 태어날때까지, 만약 모유수유를 한다면 6개월까지 엄마가 락토바실러스 람노서스(Lactobacillus rhamnosus)를 복용하고 그 후 아기들은 2세까지 425명 모든 대상 아기들이 Lactobacillus rhamnosus를 복용을 하게하여 4년간 연구한 것이다. 반면 대조군은 특정비피더스균(Bifidobacterium animalis subsp lactis)과 위약을 복용하도록 했다. (참고로 람노서스 복용단위는 HN001; 6 × 109 colony-forming units [cfu]/day 입니다.)
The cumulative prevalence of eczema by age 4 years was significantly reduced in the children taking HN001 (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.39 - 0.83) compared with in the children in the placebo group. The prevalence of rhinoconjunctivitis at age 4 years (relative risk, 0.38; 95% CI, 0.18 - 0.83) was also significantly reduced in the children in the HN001 group compared with in the children in the placebo group. HN019 did not affect the prevalence of any outcome relative to placebo.
락토바실러스 람노서스(Lactobacillus rhamnosus) 복용한 군에서 대조군에 비해서 4세까지 아토피 습진 발생확률이 현저히 감소하였으며 비결막염의 발생률도 현저히 감소하였다.
"There have been a number of primary prevention studies investigating the effects of different species of probiotics taken by pregnant or breastfeeding mothers and/or their infants on the prevalence of eczema and sensitization by age 2 years.
Reaching a consensus on the role of probiotics as primary preventers of allergic disease has been hampered by heterogeneity between studies in probiotic species and dose, duration and timing of intervention, and definitions of outcomes measured," the authors write.
The researchers previously published the initial results of their double-blind, randomized, placebo-controlled trial, in which they evaluated the effect of the probiotics on allergic disease and atopic sensitization in children in the first 2 years of life,
in the October 2008 issue of the Journal of Allergy and Clinical Immunology (2008;122:788-794). That analysis demonstrated a 49% reduction in eczema prevalence in children receiving HN001 supplementation.
이미 이전부터 유산균제와 아토피, 알레르기에 관한 연구가 활발히 진행되어 왔는데 2008년 연구에 의하면 락토바실러스 람노서스(Lactobacillus rhamnosus)를 먹은 아이들은 49% 나 습진발병율이 줄었다는 보고가 있다.
The current analysis demonstrates that the benefits of HN001 persist to age 4 years, despite cessation of therapy 2 years earlier, suggesting that this probiotic might be an appropriate preventative intervention for high-risk infants.
현재 연구 결과는 락토바실러스 람노서스(Lactobacillus rhamnosus)를 2년정도 일찍 중단해도 4세까지 그 예방효과가 지속될 수 있다고 한다.
The researchers collected data regarding the presence (since the child turned 2 years old) of eczema and any history of asthma or hay fever. They assessed eczema severity using the Scoring Atopic Dermatitis (SCORAD) scale, with a cutoff of 10 or higher, and performed skin-prick tests on the child's forearm in accordance with the Australasian Society of Clinical Immunology and Allergy guidelines. They also evaluated the prevalence of current asthma symptoms, using standard International Study of Asthma and
Allergies in Childhood questions.
In addition to significantly reducing the risk of eczema by 4 years of age, the use of the HN001 probiotic also provided some protection against SCORAD≥10, wheeze, and atopic sensitization by age 4 years. However, the protective effects did not reach statistical significance.
Fecal samples from a subset of children (n = 153) were analyzed using real-time polymerase chain reaction for the presence of L rhamnosus and B animalis. The researchers noted that HN019 was not detectable in the feces, but HN001 (or HN001-like strains) was detected in 33% of children.
The researchers had previously shown that there was no difference between study groups for sex, ethnicity, delivery, birth weight, length and head circumference, breast-feeding duration, smoking in pregnancy or in the household, pet ownership, family history of allergic disease, or antibiotic use before age 2 years.
Some of the children (24%) had received nonstudy commercially available probiotic supplements; however, exclusion of these children from the analysis did not alter relative risk estimates.
The authors acknowledge study limitations such as the unblinding of participants after 2 years of age, which may have biased responses to questions about eczema frequency and severity. The misclassification of infectious rhinitis as allergic rhinitis and asthma at 4 years of age may also have affected the results, but the authors report that this would not have had a significant effect on the study findings.
"Ours is the only study to separately evaluate two different probiotics, and show an effect for HN001 but not HN019. The different effects we found for each probiotic at age 2 years persisted to 4 years, highlighting the importance of the particular probiotic in allergic disease prevention. Another strength of our study is the high response rate (>86% of eligible infants in each group) and follow-up beyond infancy," Dr. Wickens and colleagues write.
길게 써 있지만 간단히 정리하면 락토바실러스 람노서스(Lactobacillus rhamnosus)가 아토피 슺습진과 비결막염을 줄이는데 효과가 있었으나 특정비피더스균은 효과가 없었다고 한다.
다시정리하면
신생아 아토피 예방을 위해서는 락토바실러스 람노서스(Lactobacillus rhamnosus)를 엄마나 아기나 복용하는 것이 좋으며 아토피 발병율을 거의 절반 줄일수 있다는 것입니다. 그리고 그 효과는 2세까지 먹이고 그만두어도 적어도 4세까지 지속될 수 있다는것입니다.
이미 수차례 락토바실러스 람노서스(Lactobacillus rhamnosus)가 아토피나 알레르기등을 줄일수 있다는 연구결과가 나온 상태에서 다시한번 그 효능이 검증된 연구입니다. 임신중 아기가 아토피일까바 걱정되시거나 신생아 아토피가 있다면 한번쯤 시도해볼만 하다고 봅니다. 유산균제 복용이니 무엇보다 안전하고 손쉬운 방법이겠지요.. 정장제로 소아과에서 많이 처방되는 종류인것 같구요..
우리나라에 락토바실러스 람노서스(Lactobacillus rhamnosus)가 있는지 확인해보니 한화제약에서 람노스라는 제품이 나오고 있네요. 검색하다가 발견한 블로그인데 제품 사진과 설명이 있으니 참고하시구요.. 일반 의약품이라 근처 약국에 주문을 해두면 될 것 같습니다. 성인이면 알약, 유아면 과립을 주문해서 먹으면 될 것 같습니다. 저도 한번 알아봐야겠네요..
http://blog.naver.com/musicwill3?Redirect=Log&logNo=40107258905
(끝)
